Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening strategies: a clinical perspective

E P DeAntoni1

  • 1Division of Urology, University of Colorado Health Sciences Center, Denver 80262, USA.

Cancer Surveys
|January 1, 1995
PubMed
Summary

Prostate cancer incidence is rising due to longer lifespans. Early detection using prostate-specific antigen (PSA) and advanced markers improves outcomes for this common cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and natural history of urinary symptoms in a longitudinal national prostate cancer screening (community-based) study.

Prostate cancer and prostatic diseases·2002
Same author

A cross-sectional study of vasectomy, time since vasectomy and prostate cancer.

Prostate cancer and prostatic diseases·2002
Same author

Computer modeling of prostate biopsy: tumor size and location--not clinical significance--determine cancer detection.

The Journal of urology·1998
Same author

Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor volume, grade, tumor doubling time and life expectancy.

The Journal of urology·1998
Same author

Eight years of "Prostate Cancer Awareness Week": lessons in screening and early detection. Prostate Cancer Education Council.

Cancer·1997
Same author

Prostate cancer clinical trials of the Southwest Oncology Group.

Oncology (Williston Park, N.Y.)·1997

Area of Science:

  • Oncology
  • Urology
  • Public Health

Background:

  • Prostate cancer incidence is increasing, particularly in aging Western populations.
  • Screening and early detection facilitate identifying the disease at earlier, more treatable stages.
  • Prostate-specific antigen (PSA) is a key biomarker for prostate cancer detection.

Purpose of the Study:

  • To review the evolving understanding of prostate cancer natural history.
  • To discuss advancements in prostate-specific antigen (PSA) analytical methods for improved accuracy.
  • To propose a new paradigm for defining clinically significant prostate cancer.

Main Methods:

  • Review of current literature on prostate cancer epidemiology and detection.
  • Analysis of advancements in prostate-specific antigen (PSA) testing, including PSA density, age-specific ranges, and PSA velocity.
  • Discussion of the shift from clinical disease characteristics to improved diagnostic tools for defining disease significance.

Main Results:

  • Improved diagnostic tools and public awareness are changing prostate cancer dynamics.
  • The prevalence of advanced prostate cancer is decreasing.
  • New insights are emerging for identifying clinically significant disease.

Conclusions:

  • The definition of clinically significant prostate cancer requires a new paradigm.
  • This new model should build upon, but not be limited by, older understandings.
  • Accurate detection and definition are crucial for effective prostate cancer management.

Related Experiment Videos